Mann JFE, et al. – In the LEADER trial, researchers showed the cardiovascular benefits of liraglutide treatment in type 2 diabetic patients at high cardiovascular risk who were on standard of care. However, the impact liraglutide on cardiovascular events and all-cause mortality in patients with type 2 diabetes and chronic kidney disease has yet to be understood. Therefore, researchers investigated the effects of liraglutide treatment in patients with and without kidney disease in this post hoc analysis. In addition to standard of care, patients were randomized (1:1) to liraglutide or placebo. Patients with type 2 diabetes and chronic kidney disease displayed reduced risk for major cardiovascular events and all-cause mortality with liraglutide treatment plus standard of care vs placebo.